Previous 10 | Next 10 |
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with this Read more ...
-- Horizon data at American College of Rheumatology Annual Meeting also cite the need for vigilance in treating gout among kidney transplant recipients -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a patient case series at the American College of Rheuma...
Horizon Therapeutics plc (Nasdaq: HZNP) has been awarded a Top Workplaces 2019 honor by the Chicago Tribune . This is the fifth consecutive year Horizon has received this honor. “We take tremendous pride in being named a Top Workplaces company by the Chicago Tribune ,” s...
Horizon Therapeutics plc (HZNP) Q3 2019 Results Conference Call November 06, 2019 08:00 AM ET Company Participants Tina Ventura - SVP, IR Tim Walbert - Chairman, President and CEO Shao-Lee Lin - EVP, Head, R&D and Chief Scientific Officer Paul Hoelscher - EVP and CFO Vikr...
Image source: The Motley Fool. Horizon Pharma PLC (NASDAQ: HZNP) Q3 2019 Earnings Call Nov 6, 2019 , 8:00 a.m. ET Operator Continue reading
Horizon Pharma (NASDAQ: HZNP ): Q3 Non-GAAP EPS of $0.64 beats by $0.14 ; GAAP EPS of $0.09 beats by $0.02 . Revenue of $335.5M (+3.1% Y/Y) beats by $4.9M . Press Release More news on: Horizon Therapeutics Public Limited Company, Earnings news and commentary, Healthcare stocks new...
-- Third-Quarter 2019 Net Sales of $335.5 Million Increased 3 Percent; Third-Quarter 2019 GAAP Net Income of $18.2 Million; Adjusted EBITDA of $130.4 Million -- -- Record Quarterly Orphan and Rheumatology Segment Net Sales of $250.4 Million, an Increase of 14 Percent; Segment Rep...
- Research, interactive features and charitable opportunity support advancement of care - Horizon Therapeutics plc (Nasdaq: HZNP) will join the leading voices in the nephrology community this week to inform and build data-based discourse on managing the challenges of gout and kidney di...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced an integrated analysis of efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab will be presented during an oral session at the American College of Rheumatology (ACR) Annual Meeting, Nov. 8-13 in Atlanta. The U.S. Fo...
-- Data to be presented from in-practice clinician case series on novel immunomodulation strategy -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced multiple presentations that will highlight the serious, systemic effect of urate deposition and will inform strategies to optimiz...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...